CX-5461 significantly reduced tumor incidence (37.5% (3/8 mice) in the CX-5461 group versus 87.5% (7/8 mice) in the control group; P < 0.05), tumor number (P < 0.05), and tumor burden (P < 0.05) (Fig. 6c–e; Supplementary Table 1), suggesting that CX-5461 inhibited CRC development induced by ZNF545 loss. This evidence concerns the gene ZFP82 and colorectal carcinoma.